Aardvark Therapeutics (NASDAQ:AARD) Given Neutral Rating at BTIG Research

BTIG Research reaffirmed their neutral rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note released on Monday,Benzinga reports.

A number of other brokerages have also weighed in on AARD. Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright restated a “neutral” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $6.00 price objective on shares of Aardvark Therapeutics in a report on Thursday, September 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Aardvark Therapeutics currently has an average rating of “Hold” and an average target price of $13.12.

Aardvark Therapeutics Stock Down 6.5%

Shares of NASDAQ:AARD opened at $4.45 on Monday. The firm has a market cap of $97.37 million, a P/E ratio of -1.39 and a beta of 3.80. Aardvark Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.60. The company’s 50-day moving average price is $5.88 and its two-hundred day moving average price is $5.29.

Aardvark Therapeutics (NASDAQ:AARD) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. As a group, equities analysts predict that Aardvark Therapeutics will post -3.17 earnings per share for the current fiscal year.

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the transaction, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 17.80% of the company’s stock.

Institutional Trading of Aardvark Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AARD. Bank of New York Mellon Corp raised its position in shares of Aardvark Therapeutics by 30.8% in the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock valued at $111,000 after acquiring an additional 6,905 shares during the period. Susquehanna International Group LLP acquired a new position in Aardvark Therapeutics during the second quarter valued at approximately $138,000. Ieq Capital LLC acquired a new position in Aardvark Therapeutics during the second quarter valued at approximately $221,000. J. Goldman & Co LP acquired a new position in Aardvark Therapeutics during the second quarter valued at approximately $233,000. Finally, Renaissance Technologies LLC bought a new stake in Aardvark Therapeutics in the first quarter valued at approximately $267,000.

Key Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: BTIG Research reaffirmed its “neutral” rating on AARD, signaling no change in the firm’s near-term outlook. Aardvark Therapeutics’ Neutral Rating Reaffirmed at BTIG Research
• Negative Sentiment: Several law firms, including Rosen Law Firm, Faruqi & Faruqi, Hagens Berman, DJS Law Group and Schall, Brown & Schwartz, reminded investors about a securities class action against Aardvark. The case concerns purchases tied to the company’s February 2025 IPO and securities acquired from February 13, 2025, through May 14, 2026. AARD Final Deadline Alert
• Negative Sentiment: The repeated legal announcements do not represent a new operating update, but they increase visibility around allegations of securities-law violations and potential investor losses. Investors have until October 13, 2026, to seek appointment as lead plaintiff. The allegations have not been proven, but the litigation represents a potential financial, reputational and management distraction for Aardvark. AARD Investor Securities Fraud Lawsuit Deadline

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.